A commentary questions the characterization of cryoprecipitate, which is not pathogen-reduced, as an alternative modality for treating hemophilia, despite its substantial risk of transmitting blood-borne pathogens to patients.
The current therapeutic landscape of hemophilia A in the United States is driven by several approved therapies. The hemophilia A market is estimated to grow for the period 2019–2032. The major reason behind the hemophilia A market upsurge is the launch of the most anticipated gene therapies, which are considered as a threat to the current hemophilia A market.New York, USA, Oct. 09, 2023 (GLOBE NEWSWIRE) Hemophilia A Market to Exhibit Growth at a Remarkable CAGR During the Study Period (2019-2
Although gene therapy is anticipated to bring positive changes for people with hemophilia, choosing to receive gene therapy will require empowerment, participation, and shared decision-making, investigators write.
The sBLA is supported by the results of the XTEND-Kids study, demonstrating a once-weekly 50 IU/kg dose of antihemophilic factor (recombinant) provides effective bleed protection in children with hemophilia A and can be used across clinical scenarios.